Status:
RECRUITING
Characterizing the Inflammation Around Dental Implants: Bacterial Infection, Hypersensitivity or Both?
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions:
Dental Implant Failed
Implant Complication
Eligibility:
All Genders
18+ years
Brief Summary
The use of titanium dental implants has become a common modern treatment to restore teeth. Although the success rate of dental implants is high, inflammation around the dental implant still occurs. Th...
Detailed Description
The objective of the study is to: 1. Establish the levels of cytokines in peri-implant crevicular fluid and test the levels of cytokines associated with hypersensitivity (Type 2: Interleukin-4 \[IL-4...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Received at least one functional implant (implant restored with a prothesis);
- Did not receive peri-implant mucositis and peri-implantitis treatment in the past three months.
- Exclusion criteria:
- Dental records with incomplete information;
- Individuals with a weak immune system or chronic disease such as diabetes, heart, lung or kidney disease;
- Pregnant women;
- Individuals undergoing orthodontic therapy and those who have oral piercing.
- History of diseases that modify or suppress the immune and inflammatory response, including rheumatoid arthritis, diabetes, lupus, and inflammatory bowel disease and metastatic cancer;
- Taking medications that cause antiresorptive osteonecrosis of the jaw (including any dose of intravenous bisphosphonates, oral bisphosphonate intake for more than three years, receptor activator of nuclear factor kappa-B ligand inhibitors, or antiangiogenic medications);
- Taking medications known to induce gingival hyperplasia including anticonvulsants, immunosuppressants, or calcium channel blockers;
- Taking steroid medications, systemic or local antibiotics in the last three months (as this may affect the interleukins activity);
- Received radiation therapy to the head and neck or chemotherapy;
- Received treatment to manage an inflamed implant, including management of peri-implantitis and peri-implant mucositis in the last three months.
Exclusion
Key Trial Info
Start Date :
September 22 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06515886
Start Date
September 22 2022
End Date
December 1 2025
Last Update
July 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Montreal General Hospital - Oral & Maxillofacial Surgery Clinic
Montreal, Quebec, Canada, H3G 1A4